1 års avkastning (CAGR)
-2.17%
ALK-Abelló A/S Exchange (CO, DKK)
ALK-B.CO
207.00
+2.10 (+1.07%)
HealthcareBiotechnology
Loading...
3 års avkastning (CAGR)
33.12%
5 års avkastning (CAGR)
7.78%
10 års avkastning (CAGR)
15.69%
Adobe 2026 Q3 – Drivs priset av sentimentet?
Läs merMarknadsvärde
40.00B
Pris/omsättning
5.86
Ent-värde
41.05B
Pris/bok
5.76
Direktavkastning
0.00%
Tillväxt år
-
Utdelningens tillväxt
-
FCF-utbetalning
18.84%
Efterföljande P/E
29.50
PEG
-
Fremtidig P/E
27.46
EPS-tillväxt
116.41%
Information om aktier
Vad är en börs? Funktion, aktörer, exempel
Läs merAktiediagram
Loading...
Uppgifter om aktiekurs
| Öppning | 196.10 |
| Dagens högsta | 200.20 |
| Daglig låg | 196.00 |
| Daglig volym | 201K |
| Den högsta någonsin | 270.40 |
| 1 års analytikeruppskattning | 293.75 |
| Beta | 0.70 |
| EPS (TTM) | 6.11 |
| Utdelning per aktie | 0.00 |
| Ex-div datum | 17 Mar 2026 |
| Nästa datum för resultatpresentation | 20 Feb 2026 |
Potential på nackdelen
Loading...
Negativa potentiella data
| ALK-B.CO | S&P500 | |
| Nuvarande prisfall från toppnotering | -23.45% | -1.06% |
| Högsta prisfallet | -82.39% | -56.47% |
| Datum för högsta fall | 10 Aug 2011 | 9 Mar 2009 |
| Genomsnittligt fall från topp | -34.19% | -10.67% |
| Genomsnittlig tid till ny topp | 35 days | 12 days |
| Maxtid till ny topp | 3100 days | 1805 days |
Nyheter
ALK-Abelló Pharmaceuticals Inc. Canada (ALK Canada) today announced that the Canadian Drug Expert Committee (CDEC) of Canada's Drug Agency (CDA-AMC) has issued a positive recommendation to reimburse n...
1 oktober 2026
ALK-Abelló (CPSE:ALK B) has reshuffled its top ranks, appointing Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy, effective 1 October 2026, as investors wei...
23 september 2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that the company’s Executive Vice President and CFO, Claus Steensen Sølje, is scheduled to participate in a fireside chat at the Morgan Stanley...
11 september 2026
Alk-Abello AS (AKBLF) reports 18% revenue growth in Q2, driven by record tablet sales exceeding DKK1 billion, and raises full-year revenue outlook to 14%-16%.
20 augusti 2026
Wondering whether ALK-Abelló at DKK266.20 is still reasonably priced, or if the recent optimism has already been baked into the stock. The share price sits at DKK266.20 after returns of 0.4% over the ...
5 juni 2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the f...
8 april 2026
The current standard of care for food allergy focuses on strict avoidance of the offending allergen and the prompt use of an adrenaline auto-injector (AAI) in the event of an allergic reaction. While ...
27 juli 2026
ALK-Abelló (CPSE:ALK B) has drawn fresh attention after recent trading data showed a 1.5% daily return and a 7.2% gain over the past week, prompting investors to reassess the allergy specialist. See o...
2 maj 2026
Inside Information Agreement provides long-term expanded access to Catalent's fast-dissolving (Zydis®) tablet formulation technology.Supply robustness secured with prioritised manufacturing capacity i...
30 september 2026
Tina A. Olesen, Executive Vice President for Corporate, Portfolio and Product Strategy Tina A. Olesen has been appointed Executive Vice President for Corporate, Portfolio and Product Strategy at ALK, ...
21 september 2026